[go: up one dir, main page]

MX2020013625A - Agonistas del receptor de glp-1 y usos de los mismos. - Google Patents

Agonistas del receptor de glp-1 y usos de los mismos.

Info

Publication number
MX2020013625A
MX2020013625A MX2020013625A MX2020013625A MX2020013625A MX 2020013625 A MX2020013625 A MX 2020013625A MX 2020013625 A MX2020013625 A MX 2020013625A MX 2020013625 A MX2020013625 A MX 2020013625A MX 2020013625 A MX2020013625 A MX 2020013625A
Authority
MX
Mexico
Prior art keywords
glp
receptor agonists
aza
compounds
agonists
Prior art date
Application number
MX2020013625A
Other languages
English (en)
Other versions
MX389121B (es
Inventor
Allyn T Londregan
Scott W Bagley
John M Curto
Mark E Flanagan
David A Griffith
Chris Limberakis
Alan M Mathiowetz
David W Piotrowski
Roger B Ruggeri
Gary Erik Aspnes
David James Edmonds
Kentaro Futatsugi
Kim Huard
Yajing Lian
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2020013625A publication Critical patent/MX2020013625A/es
Publication of MX389121B publication Critical patent/MX389121B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/40—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/02—Formic acid
    • C07C53/06—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/08—Acetic acid
    • C07C53/10—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)

Abstract

Se proporcionan en la presente ácidos 6-carboxílicos de bencimidazoles y 4-aza-, 5-aza- y 7-aza-bencimidazoles como agonistas de GLP-1R, procesos para elaborar tales compuestos y métodos que comprenden administrar tales compuestos a un mamífero en necesidad de los mismos.
MX2020013625A 2018-06-13 2019-06-11 Agonistas del receptor de glp-1 y usos de los mismos MX389121B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862684696P 2018-06-13 2018-06-13
US201962846944P 2019-05-13 2019-05-13
US201962851206P 2019-05-22 2019-05-22
PCT/IB2019/054867 WO2019239319A1 (en) 2018-06-13 2019-06-11 Glp-1 receptor agonists and uses thereof

Publications (2)

Publication Number Publication Date
MX2020013625A true MX2020013625A (es) 2022-01-04
MX389121B MX389121B (es) 2025-03-20

Family

ID=67003576

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013625A MX389121B (es) 2018-06-13 2019-06-11 Agonistas del receptor de glp-1 y usos de los mismos

Country Status (40)

Country Link
US (6) US10934279B2 (es)
EP (2) EP3806955B9 (es)
JP (1) JP6916968B1 (es)
KR (1) KR102542199B1 (es)
CN (4) CN119462622A (es)
AU (1) AU2019285491B2 (es)
BR (1) BR112020024470A2 (es)
CA (1) CA3045644C (es)
CL (1) CL2020003222A1 (es)
CO (1) CO2020015305A2 (es)
CR (1) CR20200612A (es)
CU (1) CU20200099A7 (es)
CY (1) CY1126097T1 (es)
DK (2) DK3806955T3 (es)
EC (1) ECSP20078651A (es)
ES (2) ES2949954T3 (es)
FI (2) FI3806955T3 (es)
GE (2) GEP20227453B (es)
HR (2) HRP20230631T1 (es)
HU (2) HUE063074T2 (es)
IL (1) IL279300B2 (es)
LT (2) LT4219487T (es)
MA (1) MA64510B1 (es)
MD (2) MD4219487T3 (es)
MX (1) MX389121B (es)
MY (1) MY199157A (es)
NI (1) NI202000091A (es)
NZ (1) NZ770240A (es)
PE (2) PE20240584A1 (es)
PH (1) PH12020552069A1 (es)
PL (2) PL4219487T3 (es)
PT (2) PT3806955T (es)
RS (2) RS64323B9 (es)
SG (1) SG11202011465QA (es)
SI (2) SI3806955T1 (es)
TW (1) TWI707683B (es)
UA (1) UA124371C2 (es)
UY (1) UY38261A (es)
WO (1) WO2019239319A1 (es)
ZA (1) ZA202007572B (es)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10934279B2 (en) * 2018-06-13 2021-03-02 Pfizer Inc. GLP-1 receptor agonists and uses thereof
WO2019239371A1 (en) 2018-06-15 2019-12-19 Pfizer Inc. Glp-1 receptor agonists and uses thereof
IL283322B2 (en) * 2018-11-22 2025-08-01 Qilu Regor Therapeutics Inc GLP-1R agonists and their uses
US10954221B2 (en) 2019-04-12 2021-03-23 Qilu Regor Therapeutics Inc. GLP-1R agonists and uses thereof
CA3140972C (en) * 2019-05-20 2024-06-18 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
TWI751585B (zh) 2019-06-28 2022-01-01 美商美國禮來大藥廠 類升糖素肽1受體促效劑
MX2022004874A (es) 2019-10-25 2022-05-13 Gilead Sciences Inc Compuestos de modulacion de glp-1r.
AU2020401539B2 (en) 2019-12-10 2023-06-01 Eli Lilly And Company Process and intermediate for the preparation of oxetan-2-ylmethanamine
JP2021091683A (ja) * 2019-12-10 2021-06-17 ファイザー・インク ２−（（４−（（Ｓ）−２−（５−クロロピリジン−２−イル）−２−メチルベンゾ［ｄ］［１，３］ジオキソール−４−イル）ピペリジン−１−イル）メチル）−１−（（（Ｓ）−オキセタン−２−イル）メチル）−１Ｈ−ベンゾ［ｄ］イミダゾール−６−カルボン酸の１，３−ジヒドロキシ−２−（ヒドロキシメチル）プロパン−２−アミン塩の固体形態
EP4097097B1 (en) * 2020-01-29 2025-01-15 Gilead Sciences, Inc. Glp-1r modulating compounds
MX2022009524A (es) 2020-02-07 2023-01-11 Gasherbrum Bio Inc Agonistas heterociclicos de glp-1.
TW202144340A (zh) * 2020-04-03 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
CN113493447B (zh) * 2020-04-03 2024-06-11 轩竹(北京)医药科技有限公司 Glp-1受体激动剂
US20230295154A1 (en) * 2020-04-29 2023-09-21 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
US20230234968A1 (en) * 2020-06-10 2023-07-27 Medshine Discovery Inc. Methyl-substituted benzobisoxazole compound and use thereof
CN113816948B (zh) * 2020-06-19 2023-08-11 江苏恒瑞医药股份有限公司 稠合咪唑类衍生物、其制备方法及其在医药上的应用
CN115916772B (zh) * 2020-06-19 2025-01-14 江苏恒瑞医药股份有限公司 6-氧代-3,6-二氢吡啶类衍生物、其制备方法及其在医药上的应用
TW202214622A (zh) * 2020-08-06 2022-04-16 大陸商上海齊魯銳格醫藥研發有限公司 Ｇｌｐ－１ｒ促效劑及其用途
WO2022028572A1 (en) 2020-08-06 2022-02-10 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
EP4204415A4 (en) * 2020-08-28 2025-03-26 Gasherbrum Bio, Inc. HETEROCYCLIC GLP-1 AGONISTS
CN119930604A (zh) 2020-09-01 2025-05-06 江苏恒瑞医药股份有限公司 稠合咪唑类衍生物、其制备方法及其在医药上的应用
WO2022068772A1 (zh) * 2020-09-29 2022-04-07 深圳信立泰药业股份有限公司 一种苯并咪唑类衍生物及其制备方法和医药用途
JP2023546055A (ja) * 2020-10-13 2023-11-01 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
CN114478694A (zh) * 2020-11-13 2022-05-13 成都奥达生物科技有限公司 一种长效mc4r激动剂
US11851419B2 (en) 2020-11-20 2023-12-26 Gilead Sciences, Inc. GLP-1R modulating compounds
WO2022111624A1 (zh) 2020-11-27 2022-06-02 深圳信立泰药业股份有限公司 一种苯并咪唑类衍生物及其制备方法和医药用途
CN114591308B (zh) * 2020-12-03 2024-03-08 苏州闻泰医药科技有限公司 一类glp-1r受体激动剂化合物及其用途
US20220193063A1 (en) * 2020-12-15 2022-06-23 Pfizer Inc. Metabolites of glp1r agonists
US12065434B2 (en) 2020-12-15 2024-08-20 Pfizer Inc. Metabolites of GLP1R agonists
CR20230330A (es) 2021-01-28 2023-11-15 Carmot Therapeutics Inc Agonistas del receptor gpcr, composiciones farmaceuticas que los comprenden y métodos para su uso
WO2022184849A1 (en) 2021-03-04 2022-09-09 Les Laboratoires Servier Glp-1r agonists, uses and pharmaceutical compositions thereof
WO2022192428A1 (en) 2021-03-11 2022-09-15 Gilead Sciences, Inc. Glp-1r modulating compounds
EP4304712A1 (en) 2021-03-11 2024-01-17 Gilead Sciences, Inc. Glp-1r modulating compounds
US20240217966A1 (en) 2021-03-24 2024-07-04 Shionogi & Co., Ltd. Pharmaceutical composition containing glp-1 receptor agonist having fused ring
US20240182456A1 (en) * 2021-04-12 2024-06-06 Novartis Ag 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
WO2022219495A1 (en) 2021-04-12 2022-10-20 Novartis Ag 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
MX2023012418A (es) 2021-04-21 2023-10-31 Gilead Sciences Inc Compuestos de modulacion de glp-1r de carboxi-bencimidazol.
CN117177970A (zh) * 2021-04-30 2023-12-05 上海翰森生物医药科技有限公司 多环类衍生物调节剂、其制备方法和应用
CA3217720A1 (en) * 2021-05-03 2022-11-10 Xiaohui Du Benzimidazoyl glp-1 receptor agonists, pharmaceutical compositions comprising the same, and methods for their use
TWI843104B (zh) 2021-05-20 2024-05-21 美商美國禮來大藥廠 類升糖素肽1受體促效劑
CN117715906A (zh) * 2021-07-21 2024-03-15 和博医药有限公司 胰高血糖素样肽-1受体调节剂及其用途
CN113480534B (zh) * 2021-07-23 2022-05-13 广州必贝特医药股份有限公司 苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用
CN117751110A (zh) * 2021-08-04 2024-03-22 上海翰森生物医药科技有限公司 环烯类衍生物调节剂、其制备方法和应用
AU2022333115B2 (en) * 2021-08-24 2025-09-18 Tonghua Dongbao Pharmaceutical Co., Ltd. Imidazocyclic compound and application thereof
MX2024002503A (es) 2021-08-30 2024-03-15 Mindrank Ai Ltd Nuevo compuesto heterociclico sustituido con aril eter como agonista de glp1r.
US20240374587A1 (en) 2021-09-08 2024-11-14 Shionogi & Co., Ltd. Medicine for prevention and treatment of diseases linked to anti-obesity activity
PL4408840T3 (pl) 2021-09-27 2025-12-22 Terns Pharmaceuticals, Inc. Kwasy benzoimidazolokarboksylowe jako agoniści glp-1r
WO2023057429A1 (en) 2021-10-05 2023-04-13 Astrazeneca Ab Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
WO2023057414A1 (en) * 2021-10-05 2023-04-13 Astrazeneca Ab Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
JP2024536353A (ja) * 2021-10-05 2024-10-04 アストラゼネカ・アクチエボラーグ Ｇｌｐ－１受容体修飾因子と特定の２，５－ジアザビシクロ［４．２．０］オクタン
CN115991685B (zh) * 2021-10-20 2025-03-04 韶远科技（上海)有限公司 一种氧杂环丁烷-2-甲胺的制备方法
TWI843243B (zh) * 2021-10-22 2024-05-21 大陸商盛世泰科生物醫藥技術（蘇州）股份有限公司 作為glp-1受體激動劑的化合物、包含其的藥物組成物及其用途
WO2023076237A1 (en) 2021-10-25 2023-05-04 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
JPWO2023106310A1 (es) * 2021-12-07 2023-06-15
CN113974618B (zh) * 2021-12-12 2022-09-13 广西澍源智能科技有限公司 基于水峰血糖修正的无创血糖测试方法
WO2023111145A1 (en) 2021-12-16 2023-06-22 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
WO2023111144A1 (en) 2021-12-16 2023-06-22 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
WO2023116882A1 (zh) * 2021-12-23 2023-06-29 江苏恒瑞医药股份有限公司 一种glp-1受体激动剂的可药用盐、结晶形式及其制备方法
JP2024547112A (ja) * 2021-12-23 2024-12-26 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 Ｇｌｐ－１受容体作動薬の結晶形及びその調製方法
CN116354945B (zh) * 2021-12-27 2024-08-30 长春金赛药业有限责任公司 一种稠合咪唑羧酸类化合物及其制备方法和应用
EP4476216A4 (en) * 2022-02-09 2025-12-03 Gasherbrum Bio Inc GLP-1 HETEROCYCLIC AGONISTS
WO2023151575A1 (en) * 2022-02-09 2023-08-17 Gasherbrum Bio Inc. Heterocyclic glp-1 agonists
JP2025505198A (ja) * 2022-02-10 2025-02-21 ノバルティス アーゲー 肥満の治療のためのｇｌｐ１受容体の活性化因子としての２－（（４－（（ｓ）－２－（４－クロロ－２－フルオロフェニル）－２－メチルベンゾ［ｄ］［１，３］ジオキソール－４－イル）ピペリジン－１－イル）メチル）－１－（（（ｓ）－オキセタン－２－イル）メチル）－１ｈ－イミダゾール誘導体
PE20250741A1 (es) 2022-02-23 2025-03-13 Terns Pharmaceuticals Inc Compuestos como agonistas de glp-1r
WO2023164358A1 (en) * 2022-02-28 2023-08-31 Ascletis Bioscience Co., Ltd. Glp-1r modulating compounds
JP2025508097A (ja) * 2022-03-08 2025-03-21 広州市聯瑞制葯有限公司 ベンゾビシクロ系化合物及びその製造方法と応用
WO2023228023A1 (en) * 2022-05-23 2023-11-30 Pfizer Inc. Treatment of type 2 diabetes or weight management control with 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d]imidazole-6-carboxylic acid or a pharmaceutically salt thereof
AU2023337154A1 (en) * 2022-09-06 2025-03-27 Mindrank Ai Ltd. Polymorph of glp-1r agonist compound, preparation method therefor, and use thereof
EP4592285A1 (en) 2022-09-22 2025-07-30 Shionogi & Co., Ltd. Fused ring compound having glp-1 receptor agonist effect
AU2023377707A1 (en) 2022-11-11 2025-05-15 Eli Lilly And Company Glucagon-like peptide 1 receptor agonists
CR20250178A (es) 2022-11-16 2025-06-06 Lilly Co Eli Agonistas del receptor del péptido-1 similar al glucagón
CN115785066B (zh) 2022-12-08 2024-05-31 广东工业大学 曲格列汀晶型f及其制备方法
WO2024149080A1 (zh) 2023-01-13 2024-07-18 中国科学院上海药物研究所 用作glp-1受体激动剂的4-烷氧基苯并咪唑-6-羧酸衍生物
EP4660194A1 (en) * 2023-02-02 2025-12-10 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Salt and crystal form of cycloalkene compound, and preparation method therefor and use thereof
WO2024169952A1 (en) 2023-02-16 2024-08-22 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
KR20250166323A (ko) 2023-04-07 2025-11-27 테른스 파마슈티칼스, 인크. 간 장애 또는 심장대사 질환의 치료에 사용하기 위한 thr베타 효현제 및 glp-1r 효현제를 포함하는 조합
KR20250172881A (ko) 2023-04-14 2025-12-09 화이자 인코포레이티드 글루코스-의존성 인슐린 분비 촉진 폴리펩티드 수용체 길항제 및 이의 용도
CN118812522A (zh) * 2023-04-21 2024-10-22 苏州闻泰医药科技有限公司 一种glp-1r受体激动剂化合物盐、其晶型、其制备方法和应用
WO2025015269A1 (en) 2023-07-13 2025-01-16 Aconcagua Bio, Inc. Compounds, compositions, and methods
TW202521528A (zh) 2023-07-13 2025-06-01 美商雅空嘉閣生物公司 化合物、組合物及方法
USD1011080S1 (en) 2023-07-28 2024-01-16 Voilasophy, Llc. Yoga storage rack
WO2025057134A2 (en) 2023-09-14 2025-03-20 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
US20250163168A1 (en) 2023-11-17 2025-05-22 Pfizer Inc. Novel antibodies and antibody conjugates for the treatment of metabolic disorders
US12291530B1 (en) 2023-11-24 2025-05-06 Ascletis Pharma (China) Co., Limited GLP-1R agonist and therapeutic method thereof
WO2025140532A1 (en) * 2023-12-27 2025-07-03 Insilico Medicine Ip Limited Novel compounds as glp-1r agonists and uses thereof
TW202543613A (zh) * 2023-12-27 2025-11-16 香港商英矽智能科技知識產權有限公司 作為ｇｌｐ－１ｒ激動劑的新型化合物及其用途
WO2025158275A1 (en) * 2024-01-24 2025-07-31 Pfizer Inc. Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds
TW202539633A (zh) 2024-02-01 2025-10-16 美商輝瑞股份有限公司 葡萄糖依賴性促胰島素多肽受體拮抗劑及其用途
WO2025171341A2 (en) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity
WO2025171340A1 (en) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. The treatment of calcitonin- and/or amylin-receptor associated conditions
WO2025189141A1 (en) 2024-03-08 2025-09-12 Annapurna Bio, Inc. Methods for treating obesity and increasing weight loss
WO2025224599A1 (en) 2024-04-22 2025-10-30 Pfizer Inc. Pyrrolidine-based glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof
WO2025224648A1 (en) 2024-04-26 2025-10-30 Pfizer Inc. Oral compositions/formulations of 2-({4-[(2s)-2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof
WO2026013531A1 (en) 2024-07-10 2026-01-15 Pfizer Inc. Spiro[2.5]octane compounds

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
AU679045B2 (en) 1993-03-18 1997-06-19 Merck Sharp & Dohme Limited Benzimidazole derivatives
AR022303A1 (es) 1999-01-22 2002-09-04 Lundbeck & Co As H Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
US6271241B1 (en) 1999-04-02 2001-08-07 Neurogen Corporation Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
US6362196B1 (en) 1999-10-29 2002-03-26 Merck & Co., Inc. Method to treat pain utilizing benzimidazole NMDA/NR2B antagonists
WO2002055496A1 (en) 2001-01-15 2002-07-18 Glaxo Group Limited Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
WO2003060475A2 (en) 2002-01-10 2003-07-24 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1h-benzoimidazole analogues
ES2301833T3 (es) 2002-07-29 2008-07-01 Hoffmann La Roche Derivados de benzodioxol.
US20040127504A1 (en) 2002-09-06 2004-07-01 Cowart Marlon D. Benzimidazoles that are useful in treating sexual dysfunction
MY140489A (en) 2003-12-26 2009-12-31 Eisai R&D Man Co Ltd 1,2-di (cyclic) substituted benzene compounds
GB0412467D0 (en) 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
EP1889618A4 (en) 2005-05-27 2010-11-24 Daiichi Sankyo Co Ltd Combined drug for treating diabetes
KR20080089494A (ko) 2006-01-20 2008-10-06 스미스클라인 비참 코포레이션 화합물
CA2650401A1 (en) 2006-04-14 2007-10-25 Merck & Co., Inc. Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators
WO2008012623A1 (en) 2006-07-25 2008-01-31 Pfizer Products Inc. Benzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor
DE102007008420A1 (de) 2007-02-21 2008-08-28 Merck Patent Gmbh Benzimidazolderivate
KR20110052741A (ko) 2008-09-11 2011-05-18 에프. 호프만-라 로슈 아게 신규한 벤즈이미다졸 유도체
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
MX2011010347A (es) 2009-03-30 2011-11-29 Transtech Pharma Inc Derivados sustituidos de azoantraceno, composiciones farmaceuticas y metodos de uso de los mismos.
TWI402070B (zh) 2009-06-11 2013-07-21 Abbott Lab 抗病毒化合物
CH702192A1 (de) 2009-11-04 2011-05-13 New Dent Ag Keramisches Implantat.
CN102946882B (zh) 2010-02-02 2016-05-18 格斯有限公司 苯基丙氨酸衍生物及其作为非肽glp-1受体调节剂的用途
WO2011097491A1 (en) * 2010-02-04 2011-08-11 Glaxosmithkline Llc Benzimidazole antiviral agents
WO2011143365A1 (en) 2010-05-13 2011-11-17 Amgen Inc. Nitrogen heterocyclic compounds useful as pde10 inhibitors
HRP20161178T1 (hr) 2010-09-30 2016-11-04 Pfizer Inc. N1-PIRAZOLOSPIROKETONSKI INHIBITORI ACETIL-CoA-KARBOKSILAZE
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
US8987271B2 (en) 2010-12-22 2015-03-24 Eutropics Pharmaceuticals, Inc. 2,2′-biphenazine compounds and methods useful for treating disease
JP6129850B2 (ja) 2012-01-12 2017-05-17 武田薬品工業株式会社 Ｍｃｈ受容体拮抗剤としてのベンゾイミダゾール誘導体
WO2014127350A1 (en) 2013-02-18 2014-08-21 The Scripps Research Institute Modulators of vasopressin receptors with therapeutic potential
WO2016029146A1 (en) 2014-08-22 2016-02-25 University Of Washington Specific inhibitors of methionyl-trna synthetase
MX385777B (es) 2014-12-24 2025-03-04 Lg Chemical Ltd Derivado de biarilo como agonista de gpr120.
WO2016107603A1 (zh) 2015-01-01 2016-07-07 成都贝斯凯瑞生物科技有限公司 取代氮杂环衍生物及其应用
CA3001857A1 (en) 2015-10-14 2017-04-20 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use against stress granules
MY204050A (en) 2015-10-21 2024-08-05 Otsuka Pharma Co Ltd Benzolactam compounds as protein kinase inhibitors
LT3397631T (lt) 2015-12-29 2021-06-10 Pfizer Inc. Pakeisti 3-azabiciklo[3.1.0]heksanai kaip ketoheksokinazės inhibitoriai
TWI747889B (zh) 2016-03-16 2021-12-01 美商庫拉腫瘤技術股份有限公司 經取代之menin-mll抑制劑及使用方法
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
JOP20190060A1 (ar) 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
CN106271089B (zh) 2016-09-30 2019-01-25 英诺激光科技股份有限公司 一种激光薄膜刻蚀装置及方法
LT3555064T (lt) * 2016-12-16 2023-01-10 Pfizer Inc. Glp-1 receptoriaus agonistai ir jų naudojimas
US10934279B2 (en) * 2018-06-13 2021-03-02 Pfizer Inc. GLP-1 receptor agonists and uses thereof
CA3140972C (en) * 2019-05-20 2024-06-18 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
EP4313963A1 (en) 2021-03-24 2024-02-07 Eccogene Inc. Phenyl- [1, 3] dioxolo [4, 5-c] pyridinyl-phenyl-, phenyl- [1, 3] dioxolo [4, 5-c] pyridinyl-heteroaryl-, or phenyl- [1, 3] dioxolo [4, 5-c] pyridinyl-piperidinyl-methyl-oxetanylmethyl-1h-benzo [d] imidazole-carboxylic acid derivatives and methods of using same
US20240300928A1 (en) 2021-04-08 2024-09-12 Lg Chem, Ltd. Glp-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same

Also Published As

Publication number Publication date
ES3012643T3 (en) 2025-04-09
MD4219487T2 (ro) 2025-04-30
MD3806955T2 (ro) 2023-09-30
FI4219487T3 (fi) 2025-02-24
IL279300B1 (en) 2023-07-01
CO2020015305A2 (es) 2021-03-08
CU20200099A7 (es) 2021-08-06
GEP20237453B (en) 2023-01-10
US20250340544A1 (en) 2025-11-06
TW202015679A (zh) 2020-05-01
SI4219487T1 (sl) 2025-07-31
FI3806955T3 (fi) 2023-07-27
GEAP202215517A (en) 2022-09-12
EP4219487A1 (en) 2023-08-02
CN119462622A (zh) 2025-02-18
RS66418B9 (sr) 2025-05-30
RS64323B9 (en) 2023-11-30
KR20210019529A (ko) 2021-02-22
US10676465B2 (en) 2020-06-09
RS64323B1 (sr) 2023-08-31
HUE063074T2 (hu) 2023-12-28
MD4219487T3 (ro) 2025-05-31
PT3806955T (pt) 2023-07-20
UY38261A (es) 2020-01-31
PE20240584A1 (es) 2024-03-21
PE20211601A1 (es) 2021-08-18
CN112533674A (zh) 2021-03-19
TWI707683B (zh) 2020-10-21
HRP20250099T1 (hr) 2025-03-28
CR20200612A (es) 2021-01-20
BR112020024470A2 (pt) 2021-03-02
CN119431342A (zh) 2025-02-14
PT4219487T (pt) 2025-02-18
PL3806955T3 (pl) 2023-09-04
RS66418B1 (sr) 2025-02-28
HUE070423T2 (hu) 2025-06-28
AU2019285491B2 (en) 2021-11-11
MX389121B (es) 2025-03-20
US20210163455A1 (en) 2021-06-03
US20190382388A1 (en) 2019-12-19
CN119462621A (zh) 2025-02-18
AU2019285491A1 (en) 2020-12-17
MD3806955T3 (ro) 2024-01-31
CL2020003222A1 (es) 2021-04-30
IL279300B2 (en) 2023-11-01
KR102542199B1 (ko) 2023-06-13
RU2769715C1 (ru) 2022-04-05
EP4219487B1 (en) 2024-12-18
CA3045644C (en) 2024-01-16
CN112533674B (zh) 2024-11-15
ES2949954T9 (es) 2023-11-23
LT4219487T (lt) 2025-01-27
DK3806955T3 (da) 2023-06-26
ECSP20078651A (es) 2021-01-29
ES2949954T3 (es) 2023-10-04
EP3806955A1 (en) 2021-04-21
JP2021521265A (ja) 2021-08-26
NZ770240A (en) 2023-07-28
UA124371C2 (uk) 2021-09-01
PH12020552069A1 (en) 2021-05-31
US20190382384A1 (en) 2019-12-19
IL279300A (en) 2021-01-31
LT3806955T (lt) 2023-07-10
EP4219487B9 (en) 2025-03-26
WO2019239319A1 (en) 2019-12-19
US20190382387A1 (en) 2019-12-19
MA64510B1 (fr) 2025-03-28
SI3806955T1 (sl) 2023-08-31
SG11202011465QA (en) 2020-12-30
DK4219487T5 (da) 2025-05-19
CA3045644A1 (en) 2019-12-13
HRP20230631T1 (hr) 2023-09-29
US10934279B2 (en) 2021-03-02
NI202000091A (es) 2021-03-23
CY1126097T1 (el) 2023-11-15
EP3806955B1 (en) 2023-05-31
ZA202007572B (en) 2023-10-25
US12378230B2 (en) 2025-08-05
JP6916968B1 (ja) 2021-08-11
MY199157A (en) 2023-10-18
US10683281B2 (en) 2020-06-16
US20240059679A1 (en) 2024-02-22
DK4219487T3 (da) 2025-02-03
EP3806955B9 (en) 2023-08-23
GEP20227453B (en) 2023-01-10
PL4219487T3 (pl) 2025-03-31

Similar Documents

Publication Publication Date Title
MX2020013625A (es) Agonistas del receptor de glp-1 y usos de los mismos.
MX394736B (es) Agonistas del receptor glp-1 y usos de los mismos.
DOP2019000166A (es) Agonistas receptores de glp-1 y usos de los mismos
CL2017001760A1 (es) Compuestos co-agonistas de gip y glp-1
CL2020000422A1 (es) Composiciones de glp-1 y sus usos.
CL2015002125A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
CU24605B1 (es) Pirimidin-2-il amino-1h-pirazoles útiles como inhibidores de lrrk2
AR102712A1 (es) Agonistas parciales del receptor de insulina
MX2017002896A (es) Uso del agente de refuerzo del receptor del acido gamma-aminobutirico tipo a (gabaa) en la preparacion de un sedante y medicamento anestesico.
CL2025002456A1 (es) Agonistas heterocíclicos de glp-1
UY36455A (es) Antagonistas del receptor ep3 de prostaglandinas
UY35776A (es) ?antagonistas de receptor ep3 de prostaglandina?.
ECSP14002542A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
CR20160084A (es) Derivados de amida como agonistas del receptor del ácido lisofosfatídico
CL2016002469A1 (es) Sulfamidasa modificada y su producción
UY35947A (es) Compuestos antagonistas selectivos de n-metil-d-aspartato (nmda) subtipo nr2b y composiciones que los contienen
AR114080A1 (es) Anticuerpos pac1 y sus usos
MX2016005227A (es) Polipéptidos de acción prolongada y métodos para su producción y administración.
EA202092674A1 (ru) Агонисты рецептора glp-1 и их применение
AR101592A1 (es) Tratamiento de cáncer usando un receptor quimérico de antígeno cd123
AR093660A1 (es) Proceso para la obtencion de bioetanol y carotenos a partir de zanahoria de descarte
AR096092A1 (es) ANTICUERPOS ANTI-IGF-1R CON ABOLICIÓN DE LA UNIÓN AL FcRn Y SU UTILIZACIÓN EN EL TRATAMIENTO DE ENFERMEDADES OCULARES VASCULARES